The Zhitong Finance App learned that Yao Ming Biotech (02269) rose by more than 4%. As of press release, it had risen 4.25% to HK$43.14, with a turnover of HK$368 million.

According to news, on August 7, according to Yao Ming Biotech's official WeChat account, Yao Ming Biotech announced that it had reached an agreement with Chuangsheng Pharmaceutical to acquire Chuangsheng Pharmaceutical's process development and production base in Hangzhou, China. The base will enhance its pharmaceutical biointegration service capabilities to meet the rapidly growing project needs of customers. The transaction is expected to be completed in the third quarter of 2026. The base covers an area of over 10,000 square meters and is equipped with process development and production capacity for stock solutions and formulations.

Dr. Chen Zhisheng, CEO of Yao Ming Biotech, said that the acquisition has further enhanced the end-to-end service capabilities for the development and production of pharmaceutical solutions and formulation production. As the number of projects and commercialization needs continue to grow, we will continue to respond to the diverse needs of our customers with high quality and efficiency.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.